S&P 500   5,015.60 (+0.09%)
DOW   37,961.30 (+0.49%)
QQQ   420.93 (-0.59%)
AAPL   165.98 (-0.63%)
MSFT   403.65 (-0.15%)
META   494.29 (-1.50%)
GOOGL   154.50 (-0.97%)
AMZN   177.59 (-0.91%)
TSLA   148.60 (-0.89%)
NVDA   837.10 (-1.13%)
AMD   151.34 (-2.41%)
NIO   3.86 (-3.50%)
BABA   68.58 (-0.44%)
T   16.34 (+0.06%)
F   12.15 (+0.75%)
MU   109.95 (-1.77%)
GE   152.24 (-0.46%)
CGC   7.89 (+0.77%)
DIS   111.98 (-0.40%)
AMC   2.85 (-2.40%)
PFE   25.43 (+0.16%)
PYPL   62.14 (+0.06%)
XOM   119.73 (+1.02%)
S&P 500   5,015.60 (+0.09%)
DOW   37,961.30 (+0.49%)
QQQ   420.93 (-0.59%)
AAPL   165.98 (-0.63%)
MSFT   403.65 (-0.15%)
META   494.29 (-1.50%)
GOOGL   154.50 (-0.97%)
AMZN   177.59 (-0.91%)
TSLA   148.60 (-0.89%)
NVDA   837.10 (-1.13%)
AMD   151.34 (-2.41%)
NIO   3.86 (-3.50%)
BABA   68.58 (-0.44%)
T   16.34 (+0.06%)
F   12.15 (+0.75%)
MU   109.95 (-1.77%)
GE   152.24 (-0.46%)
CGC   7.89 (+0.77%)
DIS   111.98 (-0.40%)
AMC   2.85 (-2.40%)
PFE   25.43 (+0.16%)
PYPL   62.14 (+0.06%)
XOM   119.73 (+1.02%)
S&P 500   5,015.60 (+0.09%)
DOW   37,961.30 (+0.49%)
QQQ   420.93 (-0.59%)
AAPL   165.98 (-0.63%)
MSFT   403.65 (-0.15%)
META   494.29 (-1.50%)
GOOGL   154.50 (-0.97%)
AMZN   177.59 (-0.91%)
TSLA   148.60 (-0.89%)
NVDA   837.10 (-1.13%)
AMD   151.34 (-2.41%)
NIO   3.86 (-3.50%)
BABA   68.58 (-0.44%)
T   16.34 (+0.06%)
F   12.15 (+0.75%)
MU   109.95 (-1.77%)
GE   152.24 (-0.46%)
CGC   7.89 (+0.77%)
DIS   111.98 (-0.40%)
AMC   2.85 (-2.40%)
PFE   25.43 (+0.16%)
PYPL   62.14 (+0.06%)
XOM   119.73 (+1.02%)
S&P 500   5,015.60 (+0.09%)
DOW   37,961.30 (+0.49%)
QQQ   420.93 (-0.59%)
AAPL   165.98 (-0.63%)
MSFT   403.65 (-0.15%)
META   494.29 (-1.50%)
GOOGL   154.50 (-0.97%)
AMZN   177.59 (-0.91%)
TSLA   148.60 (-0.89%)
NVDA   837.10 (-1.13%)
AMD   151.34 (-2.41%)
NIO   3.86 (-3.50%)
BABA   68.58 (-0.44%)
T   16.34 (+0.06%)
F   12.15 (+0.75%)
MU   109.95 (-1.77%)
GE   152.24 (-0.46%)
CGC   7.89 (+0.77%)
DIS   111.98 (-0.40%)
AMC   2.85 (-2.40%)
PFE   25.43 (+0.16%)
PYPL   62.14 (+0.06%)
XOM   119.73 (+1.02%)
Free Trial
ASX:VBS

Vectus Biosystems (VBS) Stock Price, News & Analysis

→ I’m officially sounding the alarm. (From Altimetry) (Ad)
Free VBS Stock Alerts
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis

About Vectus Biosystems

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, which include treatments for heart, kidney, liver, and lung diseases. Its lead compound is VB0004, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure; VB4-A32 for the treatment of liver fibrosis; and VB4-A79 for the treatment of lung fibrosis. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops Accugen consisting of AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was incorporated in 2005 and is based in North Ryde, Australia.

VBS Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive VBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vectus Biosystems and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:VBS
CUSIP
N/A
CIK
N/A
Web
www.vectusbiosystems.com.au
Phone
61 2 9662 4144
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
A($0.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-2,490,000.00
Net Margins
-174.84%
Pretax Margin
N/A
Return on Equity
-69.10%
Return on Assets
-34.23%

Debt

Debt-to-Equity Ratio
1.16
Current Ratio
3.71
Quick Ratio
0.49

Sales & Book Value

Annual Sales
$1.42 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
A$0.05 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
53,210,000
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
0.81
Ten Starter Stocks For Beginners to Buy Now Cover
Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Karen Annette Duggan
    CEO & Executive Director
  • Mr. Robert John Waring BEc
    CA, FAICD, FCIS, FFin, Company Secretary
  • Prof. Graham Jon MacDonald AM
    BS, BSc (Med), FANZCC, FRACP, FRCP, M.D., Consultant

Key Competitors

View All Competitors

Insiders


This page (ASX:VBS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
Urgent alert: open this for a huge profit potential
Timothy Sykes
How Biden has already won 2024
Porter & Company